Fonte: European Journal of Medicinal Chemistry. Unidades: FFCLRP, FCFRP
Assuntos: DOENÇA DE ALZHEIMER, INIBIDORES DE ENZIMAS, PROLIFERAÇÃO CELULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHIERRITO, Talita P. C. et al. From dual binding site acetylcholinesterase inhibitors to allosteric modulators: a new avenue for disease-modifying drugs in Alzheimer's disease. European Journal of Medicinal Chemistry, v. 139, p. 773-791, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.ejmech.2017.08.051. Acesso em: 04 jul. 2024.APA
Chierrito, T. P. C., Mantoani, S. P., Roca, C., Requena, C., Perez, V. S., Castillo, W. O., et al. (2017). From dual binding site acetylcholinesterase inhibitors to allosteric modulators: a new avenue for disease-modifying drugs in Alzheimer's disease. European Journal of Medicinal Chemistry, 139, 773-791. doi:10.1016/j.ejmech.2017.08.051NLM
Chierrito TPC, Mantoani SP, Roca C, Requena C, Perez VS, Castillo WO, Moreira NCS, Pérez C, Sakamoto-Hojo ET, Takahashi CS, Barbero JJ, Cañada FJ, Campillo NE, Martinez A, Carvalho I. From dual binding site acetylcholinesterase inhibitors to allosteric modulators: a new avenue for disease-modifying drugs in Alzheimer's disease [Internet]. European Journal of Medicinal Chemistry. 2017 ; 139 773-791.[citado 2024 jul. 04 ] Available from: https://doi.org/10.1016/j.ejmech.2017.08.051Vancouver
Chierrito TPC, Mantoani SP, Roca C, Requena C, Perez VS, Castillo WO, Moreira NCS, Pérez C, Sakamoto-Hojo ET, Takahashi CS, Barbero JJ, Cañada FJ, Campillo NE, Martinez A, Carvalho I. From dual binding site acetylcholinesterase inhibitors to allosteric modulators: a new avenue for disease-modifying drugs in Alzheimer's disease [Internet]. European Journal of Medicinal Chemistry. 2017 ; 139 773-791.[citado 2024 jul. 04 ] Available from: https://doi.org/10.1016/j.ejmech.2017.08.051
